Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (Q24813451)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

0 references

1 reference

based on heuristic

inferred from title

Gunter von Minckwitz

1

0 references

6

object named as

Sibylle Loibl

0 references

author name string

Sebastian Harder

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sascha Hövelmann

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Elke Jäger

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Salah-Eddin Al-Batran

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Akin Atmaca

7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Christian Cimpoiasu

8

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Antje Neumann

9

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Aklil Abera

10

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Alexander Knuth

11

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Manfred Kaufmann

12

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Dirk Jäger

13

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Alexander B Maurer

14

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Winfried S Wels

15

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

R617-26

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

7 April 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

7 April 2017

Untangling the ErbB signalling network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

7 April 2017

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

7 April 2017

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

7 April 2017

New drugs for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Recombinant toxins for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Trastuzumab-associated cardiotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

The EGF receptor family as targets for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Recombinant Toxins for Cancer Treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 September 2017

Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

30 May 2018

Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1186%2FBCR1264

21 January 2018

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 November 2018

Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 November 2018

Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 November 2018

Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1242130

28 November 2018

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16168106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR1264

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24813451&oldid=2175281823"